SG11201406888QA - Lysin-glutamic acid dipeptide derivatives - Google Patents
Lysin-glutamic acid dipeptide derivativesInfo
- Publication number
- SG11201406888QA SG11201406888QA SG11201406888QA SG11201406888QA SG11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- peptide
- basel
- designated states
- glutamic acid
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title abstract 2
- 239000004220 glutamic acid Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000007790 solid phase Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108010091858 peptide Q Proteins 0.000 abstract 1
- 238000010647 peptide synthesis reaction Methods 0.000 abstract 1
- 108010004034 stable plasma protein solution Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168119.1A EP2664374A1 (en) | 2012-05-15 | 2012-05-15 | Lysin-glutamic acid dipeptide derivatives |
| PCT/EP2013/059759 WO2013171135A1 (en) | 2012-05-15 | 2013-05-13 | Lysin-glutamic acid dipeptide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406888QA true SG11201406888QA (en) | 2015-01-29 |
Family
ID=48430764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406888QA SG11201406888QA (en) | 2012-05-15 | 2013-05-13 | Lysin-glutamic acid dipeptide derivatives |
Country Status (21)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG11201504215PA (en) | 2012-12-21 | 2015-06-29 | Sanofi Sa | Functionalized exendin-4 derivatives |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2017162650A1 (en) | 2016-03-23 | 2017-09-28 | Bachem Holding Ag | Method for preparing glucagon-like peptides |
| WO2020208409A1 (en) * | 2019-04-10 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of peptide intermediates/modifiers |
| CN111454180A (zh) * | 2020-04-10 | 2020-07-28 | 大连阿拉宁生物技术有限公司 | 一种索马鲁肽侧链中间体及其制备方法 |
| CN113004370B (zh) * | 2021-02-09 | 2022-06-17 | 宁波绿之健药业有限公司 | 一种具有缓解高尿酸血症和调节肠道菌群的二肽及其应用 |
| EP4345104B1 (en) | 2022-09-30 | 2024-08-28 | Bachem Holding AG | Method for preparing liraglutide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264243C (en) * | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
| DE60114996T2 (de) * | 2000-03-08 | 2006-08-10 | Novo Nordisk A/S | Senkung des serum cholesterols |
| US20060258580A1 (en) * | 2003-05-14 | 2006-11-16 | Regents Of The University Of Michigan | Modulators of Nod1 signaling |
| JP2006233405A (ja) * | 2005-08-16 | 2006-09-07 | Asahi Kasei Chemicals Corp | 繊維処理剤 |
| IE20060841A1 (en) * | 2006-11-21 | 2008-05-28 | Ipsen Mfg Ireland Ltd | Boc and fmoc solid phase peptide synthesis |
| JP2008290987A (ja) * | 2007-05-28 | 2008-12-04 | Shiseido Co Ltd | Ｃｍｃ修復剤、毛髪化粧料およびｃｍｃ修復方法 |
| JP5127316B2 (ja) * | 2007-06-22 | 2013-01-23 | 旭化成ケミカルズ株式会社 | 化学機械研磨用組成物 |
| EP2799447B1 (en) * | 2008-12-15 | 2016-11-23 | Zealand Pharma A/S | Glucagon analogues |
| PL2454282T3 (pl) * | 2009-07-13 | 2015-08-31 | Zealand Pharma As | Acylowane analogi glukagonu |
| JP2011057663A (ja) * | 2009-08-11 | 2011-03-24 | Sumitomo Chemical Co Ltd | 化合物及びフォトレジスト組成物 |
| CN102286092B (zh) * | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | 利拉鲁肽的固相合成方法 |
| WO2013092703A2 (en) * | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
-
2012
- 2012-05-15 EP EP12168119.1A patent/EP2664374A1/en not_active Ceased
-
2013
- 2013-05-13 NZ NZ631215A patent/NZ631215A/en unknown
- 2013-05-13 SI SI201331208T patent/SI3127604T1/sl unknown
- 2013-05-13 EP EP16179885.5A patent/EP3127604B1/en active Active
- 2013-05-13 CN CN201380024470.5A patent/CN104271227B/zh active Active
- 2013-05-13 KR KR1020197014335A patent/KR102094928B1/ko active Active
- 2013-05-13 KR KR1020147031824A patent/KR102018160B1/ko active Active
- 2013-05-13 AU AU2013261894A patent/AU2013261894B2/en active Active
- 2013-05-13 BR BR112014028334-6A patent/BR112014028334B1/pt active IP Right Grant
- 2013-05-13 PL PL16179885T patent/PL3127604T3/pl unknown
- 2013-05-13 PL PL13722408T patent/PL2849882T3/pl unknown
- 2013-05-13 CA CA3096624A patent/CA3096624C/en active Active
- 2013-05-13 MX MX2017006522A patent/MX363728B/es unknown
- 2013-05-13 JP JP2015512007A patent/JP6162795B2/ja active Active
- 2013-05-13 ES ES16179885.5T patent/ES2692364T3/es active Active
- 2013-05-13 WO PCT/EP2013/059759 patent/WO2013171135A1/en active Application Filing
- 2013-05-13 ES ES13722408.5T patent/ES2637415T3/es active Active
- 2013-05-13 RU RU2014148530A patent/RU2640812C2/ru active
- 2013-05-13 SI SI201330739T patent/SI2849882T1/sl unknown
- 2013-05-13 SG SG11201406888QA patent/SG11201406888QA/en unknown
- 2013-05-13 MX MX2014013505A patent/MX349822B/es active IP Right Grant
- 2013-05-13 EP EP13722408.5A patent/EP2849882B1/en active Active
- 2013-05-13 HR HRP20171058TT patent/HRP20171058T1/hr unknown
- 2013-05-13 MY MYPI2014703386A patent/MY172395A/en unknown
- 2013-05-13 MY MYPI2018000443A patent/MY184184A/en unknown
- 2013-05-13 CA CA2868144A patent/CA2868144C/en active Active
- 2013-05-14 AR ARP130101662A patent/AR091044A1/es active IP Right Grant
-
2014
- 2014-10-16 ZA ZA2014/07528A patent/ZA201407528B/en unknown
- 2014-10-30 IL IL235425A patent/IL235425B/en active IP Right Grant
- 2014-11-12 US US14/539,126 patent/US9522874B2/en active Active
-
2016
- 2016-11-10 US US15/348,093 patent/US9802886B2/en active Active
-
2017
- 2017-10-11 US US15/730,585 patent/US20180029978A1/en not_active Abandoned
-
2018
- 2018-10-17 HR HRP20181696TT patent/HRP20181696T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406888QA (en) | Lysin-glutamic acid dipeptide derivatives | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201403402VA (en) | Compounds | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407860PA (en) | Exendin-4 peptide analogues | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201406945QA (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201900904PA (en) | Methods for cross coupling | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |